중추신경계(CNS) 치료제 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 질환별, 약제 클래스별, 유통 채널별, 지역별 시장 예측(2025-2034년)

Central Nervous System Therapeutics Market Size, Share, Trends, & Industry Analysis Report, By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel, and By Region - Market Forecast, 2025-2034

US $ 4,250 ￦ 6,086,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,250 ￦ 7,519,000

PDF (Multi User License)

PDF 보고서를 동일 기업 20명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,250 ￦ 8,951,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

Polaris Market Research의 최근 조사에 따르면 중추신경계 치료제 시장 규모는 2034년까지 2,655억 4,000만 달러에 이를 것으로 예측됩니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.

중추신경계(CNS) 치료제란 우울증, 간질, 파킨슨병, 알츠하이머병 등 뇌, 척수, 신경에 영향을 미치는 장애의 관리와 완화를 목적으로 한 치료를 말합니다. 이러한 치료법에는 약물 치료, 생물학적 제제, 신경 기능 및 삶의 질을 개선하기 위해 고안된 새로운 디지털 의료 및 정밀의료 접근법이 포함됩니다.

인구 고령화는 CNS 치료 시장의 강력한 촉진요인 중 하나입니다. 고령화에 따라 알츠하이머병, 파킨슨병, 치매 등의 신경질환이나 정신질환에 걸리기 쉬워집니다. 이러한 연령 관련 질환은 만성적이고 진행성이기 때문에 장기적인 치료가 필요합니다. 북미, 유럽, 아시아의 일부와 같은 세계 고령자 증가로 인해 헬스케어 시스템은 더 나은 보다 효율적인 중추 신경계 관리를 제공해야 합니다. 또한 고령자는 의료 도움을 얻고 치료 계획을 준수하는 경향이 강하기 때문에 중추신경계 질환 치료 및 치료법에 대한 안정적인 수요가 증가하고 있습니다. 이에 따라 제약회사는 신경퇴행성 질환과 노화에 따른 인지기능 저하에 관한 연구에 주력하고 있습니다. 각국 정부는 중추신경계 질환을 대상으로 하는 것을 포함하여 고령자 헬스케어 프로그램에 대한 자금 제공을 더욱 늘리고 있습니다. 세계의 노인이 증가함에 따라 효과적이고 사용하기 쉽고 안전한 중추신경계 치료제에 대한 요구가 커지고 있으며, 이는 성장을 이끌고 있습니다.

COVID-19 이후의 상황은 헬스케어의 우선순위를 재정의하고 정신적 행복과 신경학적 치료를 더욱 중시하게 되었습니다. 팬데믹은 건강 위기 시 중추신경계 치료제에 접근할 때 취약성을 돋보이게 할 뿐만 아니라 디지털 치료, 원격 치료 모델, 만성 신경 질환 관리에 대한 혁신적인 접근에 대한 수요를 증가시켰습니다. 정부와 민간 단체도 신경 퇴행성 질환과 정신 질환의 부담 증가를 배경으로 중추 신경계 연구에 대한 투자를 늘리고 있으며 성장을 견인하고 있습니다.

중추신경계 치료제 시장 보고서 하이라이트

우울증, 불안 신경증, 양극성 장애, 정신 분열증과 같은 정신 질환의 세계 증가에 견인되었으며, 예측 기간 동안 정신 건강 부문의 점유율은 26.15%에 도달할 전망입니다.

많은 중추신경계 치료제, 특히 심각한 정신 질환 및 신경혈관 질환에 대한 치료가 면밀한 의료 관리하에 병원 내에서 실시되거나 시작되기 때문에 병원 약국 부문은 2024년 554억 3,000만 달러의 매출을 차지했습니다.

북미의 중추신경계 치료제 시장은 선진적 헬스케어 인프라, 고액의 의료비, 신경질환 및 정신질환에 대한 인식 확산으로 2024년 세계 시장 점유율의 40.24%를 차지했습니다.

아시아태평양의 중추신경계 치료제 시장은 인구 많고 적음, 의료 투자 증가, 신경 질환에 대한 의식 증가로 2024년 251억 2,000만 달러의 수익을 기록했습니다.

세계 주요 시장 진출 기업은 AstraZeneca plc, Biogen Inc, Eli Lilly and Company, Johnson & Johnson, Merck & Co. 등이 있습니다.

목차

제1장 세계의 중추신경계 치료제 시장 보고서 개요

• 조사 범위
• 시장 부문 분석
• 지역 및 국가에 의한 규제 시나리오
• 시장투자 시나리오 전략
• 시장 분석 : 질환별
  • 세계의 중추신경계 치료제 시장 점유율 : 질환별(2025-2034년)
  • 신경혈관 질환
  • 중추신경계 외상
  • 정신 건강
  • 신경퇴행성 질환
    • 알츠하이머병
    • 파킨슨병
    • 다발성 경화증
    • 헌팅턴병
    • 근위축성 측삭 경화증
    • 기타
  • 감염증
  • 중추신경계암
  • 기타
• 중추신경계 치료제 시장 점유율 : 질환별(2025년, 2034년)
• 시장 분석 : 약제 클래스별
  • 세계의 중추신경계 치료제 시장 점유율 : 약제 클래스별(2025-2034년)
  • 마취약
  • 항경련제
  • 제토제
  • 중추 신경 자극제
  • 진통제
  • 기타
• 세계의 중추신경계 치료제 시장 점유율 : 약제 클래스별(2025년, 2034년)
• 시장 분석 : 유통 채널별
  • 세계의 중추신경계 치료제 시장 점유율 : 유통 채널별(2025-2034년)
  • 병원 약국
  • 소매 약국
  • 기타
• 세계의 중추신경계 치료제 시장 점유율 : 유통 채널별(2025년, 2034년)

제2장 중추신경계 치료제 시장에서 드라이버 구속의 과제 및 기회

• 추진력, 억제, 과제 및 기회의 분석
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회
  • 시장 과제

제3장 세계의 경제 성장 동향

• 산업 동향
  • SWOT 분석
    • 강점
    • 약점
    • 기회
    • 위협
  • PESTEL 분석
    • 정치
    • 경제
    • 사회
    • 기술
    • 환경
    • 법적
• 잠재 시장 및 성장 잠재력 분석

제4장 COVID-19의 영향

• COVID-19의 영향
• COVID V, U, W, L 분석
  • COVID V 분석
  • COVID U 분석
  • COVID L 분석
  • COVID-19 분석

제5장 기업 분석

• 세계의 중추신경계 치료제 시장, 판매 지역 및 제품 유형
• 세계의 중추신경계 치료제 시장에서의 합병 및 인수, 제휴, 제품 발매, 콜라보레이션
• 기업 목록

제6장 주요 요약

제7장 세계의 중추신경계 치료제 시장 예측(2021-2034년)

제8장 세계의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제9장 세계의 중추신경계 치료제 시장 : 신경변성 질환별(2021-2034년)

제10장 세계의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제11장 세계의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제12장 세계의 중추신경계 치료제 시장 : 지역별(2021-2034년)

제13장 북미의 중추신경계 치료제 시장 : 국가별(2021-2034년)

제14장 북미의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제15장 북미의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제16장 북미의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제17장 미국의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제18장 미국의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제19장 미국의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제20장 캐나다의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제21장 캐나다의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제22장 캐나다의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제23장 유럽의 중추신경계 치료제 시장 : 국가별(2021-2034년)

제24장 유럽의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제25장 유럽의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제26장 유럽의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제27장 영국의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제28장 영국의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제29장 영국의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제30장 독일의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제31장 독일의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제32장 독일의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제33장 프랑스의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제34장 프랑스의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제35장 프랑스의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제36장 스페인 중추신경계 치료제 시장 : 질환별(2021-2034년)

제37장 스페인의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제38장 스페인의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제39장 이탈리아의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제40장 이탈리아의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제41장 이탈리아의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제42장 네덜란드의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제43장 네덜란드의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제44장 네덜란드의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제45장 러시아의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제46장 러시아의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제47장 러시아의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제48장 기타 유럽의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제49장 기타 유럽의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제50장 기타 유럽의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제51장 아시아태평양의 중추신경계 치료제 시장 : 국가별(2021-2034년)

제52장 아시아태평양의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제53장 아시아태평양의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제54장 아시아태평양의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제55장 중국의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제56장 중국의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제57장 중국의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제58장 인도의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제59장 인도의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제60장 인도의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제61장 일본의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제62장 일본의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제63장 일본의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제64장 한국의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제65장 한국의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제66장 한국의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제67장 인도네시아의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제68장 인도네시아의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제69장 인도네시아의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제70장 말레이시아의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제71장 말레이시아의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제72장 말레이시아의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제73장 기타 아시아태평양의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제74장 기타 아시아태평양의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제75장 기타 아시아태평양의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제76장 라틴아메리카의 중추신경계 치료제 시장 : 국가별(2021-2034년)

제77장 라틴아메리카의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제78장 라틴아메리카의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제79장 라틴아메리카의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제80장 브라질의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제81장 브라질의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제82장 브라질의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제83장 아르헨티나의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제84장 아르헨티나의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제85장 아르헨티나의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제86장 멕시코의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제87장 멕시코의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제88장 멕시코의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제89장 기타 라틴아메리카의 중추신경계 치료제 시장 : 질환별(2021-2034년)

제90장 기타 라틴아메리카의 중추신경계 치료제 시장 : 약제 클래스별(2021-2034년)

제91장 기타 라틴아메리카의 중추신경계 치료제 시장 : 유통 채널별(2021-2034년)

제92장 중동 및 아프리카의 중추신경계 치료제 시장 : 국가별(2021-2034년)

제93장 중동 및 아프리카의 중추신경계 치료제 시장 : 질환별(2021-2034년)

AJY

영문 목차

영문목차

The central nervous system therapeutics market size is expected to reach USD 265.54 Billion by 2034, according to a new study by Polaris Market Research. The report "Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Central Nervous System (CNS) therapeutics refers to treatments aimed at managing and alleviating disorders affecting the brain, spinal cord, and nerves, such as depression, epilepsy, Parkinson's disease, and Alzheimer's. These therapies include medications, biologics, and emerging digital and precision medicine approaches designed to improve neurological function and quality of life.

An aging population is one of the strongest drivers of the CNS therapeutics market. People become more prone to neurological and mental health conditions like Alzheimer's, Parkinson's, and dementia as people age. These age-related disorders are chronic and progressive, requiring long-term medical attention and treatment. The rise in the elderly population globally in region such as North America, Europe, and parts of Asia is putting pressure on healthcare systems to provide better and more efficient CNS care. Older adults are also more likely to seek medical help and adhere to treatment plans, driving consistent demand for CNS drugs and therapies. In response, pharmaceutical companies are focusing their research efforts on neurodegenerative conditions and age-related cognitive decline. Governments are further increasing funding for elderly healthcare programs, including those targeting CNS disorders. The need for effective, accessible, and safe CNS therapeutics rise as the global senior population continues to grow, thereby driving the growth.

The post-COVID-19 landscape has redefined healthcare priorities, placing greater emphasis on mental well-being and neurological care. The pandemic not only highlighted the vulnerabilities in accessing CNS treatments during health crises but also increased demand for digital therapeutics, remote care models, and innovative approaches to managing chronic neurological conditions. Governments and private organizations are also investing more into CNS research, driven by the growing burden of neurodegenerative and psychiatric illnesses, thereby driving the growth.

Central Nervous System Therapeutics Market Report Highlights

The mental health segment accounted for 26.15% share during the forecast period driven by a global rise in psychiatric conditions such as depression, anxiety, bipolar disorder, and schizophrenia.

The hospital pharmacy segment accounted USD 55.43 billion revenue in 2024 as many CNS treatments, especially for severe mental health or neurovascular conditions, are administered or initiated in hospital settings under close medical supervision.

North America central nervous system therapeutics market accounted for 40.24% global market share in 2024 driven by advanced healthcare infrastructure, high healthcare spending, and widespread awareness of neurological and mental health conditions.

The Asia Pacific central nervous system therapeutics market recorded USD 25.12 billion revenue in 2024, due to its large population, rising healthcare investment, and increasing awareness of neurological disorders.

The global key market players are AstraZeneca plc; Biogen Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Neuraxpharm; Novartis AG; Otsuka Pharmaceutical Co., Ltd; Pfizer Inc.; Takeda Pharma Company Ltd; Teva Pharmaceutical Industries Ltd.

Polaris market research has segmented the central nervous system therapeutics market report based on Disease, drug class, distribution channel, and region:

By Disease (Revenue - USD Billion, 2020-2034)

Neurovascular Diseases

CNS Trauma

Mental Health

Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Huntington's Disease

Amyotrophic Lateral Sclerosis

Others

Infectious Diseases

CNS Cancer

Others

By Drug Class (Revenue - USD Billion, 2020-2034)

Anesthetics

Anticonvulsants

Antiemetic

CNS Stimulants

Pain Relievers

Others

By Distribution Channel (Revenue - USD Billion, 2020-2034)

Hospital Pharmacy

Retail Pharmacy

Other

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Australia

Rest of APAC

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of MEA

Table of Contents

1. Global Central Nervous System Therapeutics Market-Report Overview

• 1.1. Scope of the report
• 1.2. Market Segment Analysis
• 1.3. Regulatory Scenario by Region/Country
• 1.4. Market Investment Scenario Strategic
• 1.5. Market Analysis by Disease (USD Million)
  • 1.5.1 Global Central Nervous System Therapeutics Market Share by Disease (2025-2034)
  • 1.5.2 Neurovascular Diseases
  • 1.5.3 CNS Trauma
  • 1.5.4 Mental Health
  • 1.5.5 Neurodegenerative Diseases
    • 1.5.5.1 Alzheimer's Disease
    • 1.5.5.2 Parkinson's Disease
    • 1.5.5.3 Multiple Sclerosis
    • 1.5.5.4 Huntington's Disease
    • 1.5.5.5 Amyotrophic Lateral Sclerosis
    • 1.5.5.6 Others
  • 1.5.6 Infectious Diseases
  • 1.5.7 CNS Cancer
  • 1.5.8 Others
• 1.6. Global Central Nervous System Therapeutics Market Share by Disease in 2025 & 2034
• 1.7. Market Analysis by Drug Class (USD Million)
  • 1.7.1 Global Central Nervous System Therapeutics Market Share by Drug Class (2025-2034)
  • 1.7.2 Anesthetics
  • 1.7.3 Anticonvulsants
  • 1.7.4 Antiemetic
  • 1.7.5 CNS Stimulants
  • 1.7.6 Pain Relievers
  • 1.7.7 Others
• 1.8. Global Central Nervous System Therapeutics Market Share by Drug Class in 2025 & 2034
• 1.9. Market Analysis by Distribution Channel (USD Million)
  • 1.9.1 Global Central Nervous System Therapeutics Market Share by Distribution Channel (2025-2034)
  • 1.9.2 Hospital Pharmacies
  • 1.9.3 Retail Pharmacies
  • 1.9.4 Others
• 1.10. Global Central Nervous System Therapeutics Market Share by Distribution Channel in 2025 & 2034

2. driver restraint challenge and opportunities of Central Nervous System Therapeutics Market

• 2.1. Driver, Restraint, Challenge and Opportunities Analysis
  • 2.1.1 Market Driver Analysis
  • 2.1.2 Market Restraint Analysis
  • 2.1.3 Market Opportunity
  • 2.1.4 Market Challenges

3. Global Growth Trends

• 3.1. Industry Trends
  • 3.1.1 SWOT Analysis
    • 3.1.1.1 Strengths
    • 3.1.1.2 Weaknesses
    • 3.1.1.3 Opportunities
    • 3.1.1.4 Threats
  • 3.1.2 PESTEL Analysis
    • 3.1.2.1 Political Landscape
    • 3.1.2.2 Economic Landscape
    • 3.1.2.3 Social Landscape
    • 3.1.2.4 Technological Landscape
    • 3.1.2.5 Environmental Landscape
    • 3.1.2.6 Legal Landscape
  • 3.1.3 Porter's Five Forces Analysis
    • 3.1.3.1 Bargaining Power of Suppliers
    • 3.1.3.2 Bargaining Power of Buyers
    • 3.1.3.3 Threat of Substitute
    • 3.1.3.4 Threat of New Entrant
    • 3.1.3.5 Competitive Rivalry
• 3.2. Potential Market and Growth Potential Analysis

4. Covid-19 Impact

• 4.1. Covid-19 Impact
• 4.2. COVID V, U, W and L Analysis
  • 4.2.1 COVID V Analysis
  • 4.2.2 COVID U Analysis
  • 4.2.3 COVID L Analysis
  • 4.2.4 COVID W Analysis

5. Companies Analysis

• 5.1. Global Central Nervous System Therapeutics Market, Sales Area, Product Type
• 5.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Central Nervous System Therapeutics Market
• 5.3. Companies List

6. Exceutive Summary

7. Global Central Nervous System Therapeutics Market Forecast, 2021-2034, (USD Million)

• 7.1. Global Central Nervous System Therapeutics Market

8. Global Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 8.1. Global Central Nervous System Therapeutics Market by Disease (2021-2027)
• 8.2. Global Central Nervous System Therapeutics Market by Disease (2028-2034)

9. Global Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2034), (USD Million)

• 9.1. Global Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 9.2. Global Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

10. Global Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 10.1. Global Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 10.2. Global Central Nervous System Therapeutics Market by Drug Class (2028-2034)

11. Global Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 11.1. Global Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 11.2. Global Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

12. Global Central Nervous System Therapeutics Market by REGION (2021-2034), (USD Million)

• 12.1. Global Central Nervous System Therapeutics Market by Region (2021-2027)
• 12.2. Global Central Nervous System Therapeutics Market by Region (2028-2034)

13. North America Central Nervous System Therapeutics Market by Country (2021-2034), (USD Million)

• 13.1. North America Central Nervous System Therapeutics Market by Country (2021-2027)
• 13.2. North America Central Nervous System Therapeutics Market by Country (2028-2034)

14. North America Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 14.1. North America Central Nervous System Therapeutics Market by Disease (2021-2027)
• 14.2. North America Central Nervous System Therapeutics Market by Disease (2028-2034)
• 14.3. North America Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 14.4. North America Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

15. North America Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 15.1. North America Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 15.2. North America Central Nervous System Therapeutics Market by Drug Class (2028-2034)

16. North America Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 16.1. North America Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 16.2. North America Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

17. United States Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 17.1. United States Central Nervous System Therapeutics Market by Disease (2021-2027)
• 17.2. United States Central Nervous System Therapeutics Market by Disease (2028-2034)
• 17.3. United States Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 17.4. United States Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

18. United States Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 18.1. United States Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 18.2. United States Central Nervous System Therapeutics Market by Drug Class (2028-2034)

19. United States Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 19.1. United States Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 19.2. United States Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

20. Canada Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 20.1. Canada Central Nervous System Therapeutics Market by Disease (2021-2027)
• 20.2. Canada Central Nervous System Therapeutics Market by Disease (2028-2034)
• 20.3. Canada Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 20.4. Canada Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

21. Canada Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 21.1. Canada Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 21.2. Canada Central Nervous System Therapeutics Market by Drug Class (2028-2034)

22. Canada Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 22.1. Canada Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 22.2. Canada Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

23. Europe Central Nervous System Therapeutics Market by Country (2021-2034), (USD Million)

• 23.1. Europe Central Nervous System Therapeutics Market by Country (2021-2027)
• 23.2. Europe Central Nervous System Therapeutics Market by Country (2028-2034)

24. Europe Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 24.1. Europe Central Nervous System Therapeutics Market by Disease (2021-2027)
• 24.2. Europe Central Nervous System Therapeutics Market by Disease (2028-2034)
• 24.3. Europe Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 24.4. Europe Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

25. Europe Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 25.1. Europe Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 25.2. Europe Central Nervous System Therapeutics Market by Drug Class (2028-2034)

26. Europe Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 26.1. Europe Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 26.2. Europe Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

27. United Kingdom Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 27.1. United Kingdom Central Nervous System Therapeutics Market by Disease (2021-2027)
• 27.2. United Kingdom Central Nervous System Therapeutics Market by Disease (2028-2034)
• 27.3. United Kingdom Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 27.4. United Kingdom Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

28. United Kingdom Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 28.1. United Kingdom Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 28.2. United Kingdom Central Nervous System Therapeutics Market by Drug Class (2028-2034)

29. United Kingdom Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 29.1. United Kingdom Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 29.2. United Kingdom Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

30. Germany Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 30.1. Germany Central Nervous System Therapeutics Market by Disease (2021-2027)
• 30.2. Germany Central Nervous System Therapeutics Market by Disease (2028-2034)
• 30.3. Germany Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 30.4. Germany Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

31. Germany Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 31.1. Germany Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 31.2. Germany Central Nervous System Therapeutics Market by Drug Class (2028-2034)

32. Germany Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 32.1. Germany Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 32.2. Germany Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

33. France Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 33.1. France Central Nervous System Therapeutics Market by Disease (2021-2027)
• 33.2. France Central Nervous System Therapeutics Market by Disease (2028-2034)
• 33.3. France Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 33.4. France Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

34. France Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 34.1. France Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 34.2. France Central Nervous System Therapeutics Market by Drug Class (2028-2034)

35. France Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 35.1. France Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 35.2. France Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

36. Spain Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 36.1. Spain Central Nervous System Therapeutics Market by Disease (2021-2027)
• 36.2. Spain Central Nervous System Therapeutics Market by Disease (2028-2034)
• 36.3. Spain Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 36.4. Spain Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

37. Spain Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 37.1. Spain Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 37.2. Spain Central Nervous System Therapeutics Market by Drug Class (2028-2034)

38. Spain Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 38.1. Spain Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 38.2. Spain Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

39. Italy Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 39.1. Italy Central Nervous System Therapeutics Market by Disease (2021-2027)
• 39.2. Italy Central Nervous System Therapeutics Market by Disease (2028-2034)
• 39.3. Italy Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 39.4. Italy Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

40. Italy Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 40.1. Italy Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 40.2. Italy Central Nervous System Therapeutics Market by Drug Class (2028-2034)

41. Italy Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 41.1. Italy Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 41.2. Italy Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

42. Netherlands Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 42.1. Netherlands Central Nervous System Therapeutics Market by Disease (2021-2027)
• 42.2. Netherlands Central Nervous System Therapeutics Market by Disease (2028-2034)
• 42.3. Netherlands Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 42.4. Netherlands Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

43. Netherlands Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 43.1. Netherlands Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 43.2. Netherlands Central Nervous System Therapeutics Market by Drug Class (2028-2034)

44. Netherlands Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 44.1. Netherlands Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 44.2. Netherlands Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

45. Russia Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 45.1. Russia Central Nervous System Therapeutics Market by Disease (2021-2027)
• 45.2. Russia Central Nervous System Therapeutics Market by Disease (2028-2034)
• 45.3. Russia Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 45.4. Russia Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

46. Russia Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 46.1. Russia Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 46.2. Russia Central Nervous System Therapeutics Market by Drug Class (2028-2034)

47. Russia Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 47.1. Russia Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 47.2. Russia Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

48. Rest of Europe Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 48.1. Rest of Europe Central Nervous System Therapeutics Market by Disease (2021-2027)
• 48.2. Rest of Europe Central Nervous System Therapeutics Market by Disease (2028-2034)
• 48.3. Rest of Europe Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 48.4. Rest of Europe Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

49. Rest of Europe Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 49.1. Rest of Europe Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 49.2. Rest of Europe Central Nervous System Therapeutics Market by Drug Class (2028-2034)

50. Rest of Europe Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 50.1. Rest of Europe Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 50.2. Rest of Europe Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

51. Asia Pacific Central Nervous System Therapeutics Market by Country (2021-2034), (USD Million)

• 51.1. Asia Pacific Central Nervous System Therapeutics Market by Country (2021-2027)
• 51.2. Asia Pacific Central Nervous System Therapeutics Market by Country (2028-2034)

52. Asia Pacific Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 52.1. Asia Pacific Central Nervous System Therapeutics Market by Disease (2021-2027)
• 52.2. Asia Pacific Central Nervous System Therapeutics Market by Disease (2028-2034)
• 52.3. Asia Pacific Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 52.4. Asia Pacific Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

53. Asia Pacific Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 53.1. Asia Pacific Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 53.2. Asia Pacific Central Nervous System Therapeutics Market by Drug Class (2028-2034)

54. Asia Pacific Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 54.1. Asia Pacific Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 54.2. Asia Pacific Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

55. China Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 55.1. China Central Nervous System Therapeutics Market by Disease (2021-2027)
• 55.2. China Central Nervous System Therapeutics Market by Disease (2028-2034)
• 55.3. China Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 55.4. China Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

56. China Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 56.1. China Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 56.2. China Central Nervous System Therapeutics Market by Drug Class (2028-2034)

57. China Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 57.1. China Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 57.2. China Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

58. India Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 58.1. India Central Nervous System Therapeutics Market by Disease (2021-2027)
• 58.2. India Central Nervous System Therapeutics Market by Disease (2028-2034)
• 58.3. India Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 58.4. India Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

59. India Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 59.1. India Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 59.2. India Central Nervous System Therapeutics Market by Drug Class (2028-2034)

60. India Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 60.1. India Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 60.2. India Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

61. Japan Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 61.1. Japan Central Nervous System Therapeutics Market by Disease (2021-2027)
• 61.2. Japan Central Nervous System Therapeutics Market by Disease (2028-2034)
• 61.3. Japan Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 61.4. Japan Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

62. Japan Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 62.1. Japan Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 62.2. Japan Central Nervous System Therapeutics Market by Drug Class (2028-2034)

63. Japan Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 63.1. Japan Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 63.2. Japan Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

64. South Korea Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 64.1. South Korea Central Nervous System Therapeutics Market by Disease (2021-2027)
• 64.2. South Korea Central Nervous System Therapeutics Market by Disease (2028-2034)
• 64.3. South Korea Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 64.4. South Korea Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

65. South Korea Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 65.1. South Korea Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 65.2. South Korea Central Nervous System Therapeutics Market by Drug Class (2028-2034)

66. South Korea Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 66.1. South Korea Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 66.2. South Korea Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

67. Indonesia Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 67.1. Indonesia Central Nervous System Therapeutics Market by Disease (2021-2027)
• 67.2. Indonesia Central Nervous System Therapeutics Market by Disease (2028-2034)
• 67.3. Indonesia Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 67.4. Indonesia Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

68. Indonesia Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 68.1. Indonesia Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 68.2. Indonesia Central Nervous System Therapeutics Market by Drug Class (2028-2034)

69. Indonesia Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 69.1. Indonesia Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 69.2. Indonesia Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

70. Malaysia Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 70.1. Malaysia Central Nervous System Therapeutics Market by Disease (2021-2027)
• 70.2. Malaysia Central Nervous System Therapeutics Market by Disease (2028-2034)
• 70.3. Malaysia Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 70.4. Malaysia Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

71. Malaysia Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 71.1. Malaysia Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 71.2. Malaysia Central Nervous System Therapeutics Market by Drug Class (2028-2034)

72. Malaysia Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 72.1. Malaysia Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 72.2. Malaysia Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

73. Rest of Asia Pacific Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 73.1. Rest of Asia Pacific Central Nervous System Therapeutics Market by Disease (2021-2027)
• 73.2. Rest of Asia Pacific Central Nervous System Therapeutics Market by Disease (2028-2034)
• 73.3. Rest of Asia Pacific Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 73.4. Rest of Asia Pacific Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

74. Rest of Asia Pacific Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 74.1. Rest of Asia Pacific Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 74.2. Rest of Asia Pacific Central Nervous System Therapeutics Market by Drug Class (2028-2034)

75. Rest of Asia Pacific Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 75.1. Rest of Asia Pacific Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 75.2. Rest of Asia Pacific Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

76. Latin America Central Nervous System Therapeutics Market by Country (2021-2034), (USD Million)

• 76.1. Latin America Central Nervous System Therapeutics Market by Country (2021-2027)
• 76.2. Latin America Central Nervous System Therapeutics Market by Country (2028-2034)

77. Latin America Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 77.1. Latin America Central Nervous System Therapeutics Market by Disease (2021-2027)
• 77.2. Latin America Central Nervous System Therapeutics Market by Disease (2028-2034)
• 77.3. Latin America Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 77.4. Latin America Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

78. Latin America Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 78.1. Latin America Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 78.2. Latin America Central Nervous System Therapeutics Market by Drug Class (2028-2034)

79. Latin America Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 79.1. Latin America Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 79.2. Latin America Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

80. Brazil Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 80.1. Brazil Central Nervous System Therapeutics Market by Disease (2021-2027)
• 80.2. Brazil Central Nervous System Therapeutics Market by Disease (2028-2034)
• 80.3. Brazil Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 80.4. Brazil Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

81. Brazil Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 81.1. Brazil Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 81.2. Brazil Central Nervous System Therapeutics Market by Drug Class (2028-2034)

82. Brazil Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 82.1. Brazil Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 82.2. Brazil Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

83. Argentina Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 83.1. Argentina Central Nervous System Therapeutics Market by Disease (2021-2027)
• 83.2. Argentina Central Nervous System Therapeutics Market by Disease (2028-2034)
• 83.3. Argentina Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 83.4. Argentina Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

84. Argentina Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 84.1. Argentina Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 84.2. Argentina Central Nervous System Therapeutics Market by Drug Class (2028-2034)

85. Argentina Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 85.1. Argentina Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 85.2. Argentina Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

86. Mexico Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 86.1. Mexico Central Nervous System Therapeutics Market by Disease (2021-2027)
• 86.2. Mexico Central Nervous System Therapeutics Market by Disease (2028-2034)
• 86.3. Mexico Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 86.4. Mexico Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

87. Mexico Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 87.1. Mexico Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 87.2. Mexico Central Nervous System Therapeutics Market by Drug Class (2028-2034)

88. Mexico Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 88.1. Mexico Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 88.2. Mexico Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

89. Rest of Latin America Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 89.1. Rest of Latin America Central Nervous System Therapeutics Market by Disease (2021-2027)
• 89.2. Rest of Latin America Central Nervous System Therapeutics Market by Disease (2028-2034)
• 89.3. Rest of Latin America Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2021-2027)
• 89.4. Rest of Latin America Central Nervous System Therapeutics Market by Neurodegenerative Diseases (2028-2034)

90. Rest of Latin America Central Nervous System Therapeutics Market by Drug Class (2021-2034), (USD Million)

• 90.1. Rest of Latin America Central Nervous System Therapeutics Market by Drug Class (2021-2027)
• 90.2. Rest of Latin America Central Nervous System Therapeutics Market by Drug Class (2028-2034)

91. Rest of Latin America Central Nervous System Therapeutics Market by Distribution Channel (2021-2034), (USD Million)

• 91.1. Rest of Latin America Central Nervous System Therapeutics Market by Distribution Channel (2021-2027)
• 91.2. Rest of Latin America Central Nervous System Therapeutics Market by Distribution Channel (2028-2034)

92. Middle East & Africa Central Nervous System Therapeutics Market by Country (2021-2034), (USD Million)

• 92.1. Middle East & Africa Central Nervous System Therapeutics Market by Country (2021-2027)
• 92.2. Middle East & Africa Central Nervous System Therapeutics Market by Country (2028-2034)

93. Middle East & Africa Central Nervous System Therapeutics Market by Disease (2021-2034), (USD Million)

• 93.1. Middle East & Africa Central Nervous System Therapeutics Market by Disease (2021-2027)
• 93.2. Middle East & Africa Central Nervous System Therapeutics Market

관련자료